Divergence in MIC distributions of Pseudomonas aeruginosa for piperacillin and piperacillin/tazobactam

Journal of Infectious Disease Pharmacotherapy

Volumn 5, Issue 3, 2001, Pages 41-51

  Kuti, Joseph L ^a,b,c,d   Sutherland, Christina A ^a,b,c,d   Grant, Edward M ^a,b,c,d   Ye, Min ^a,b,c,d   Zhou, When ^a,b,c,d   McCarter, Yvette ^a,b,c,d   Nightingale, Charles H ^a,b,c,d   Nicolau, David P ^a,b,c,d  

^a HARTFORD HOSPITAL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

MIC; Piperacillin; Pseudomonas aeruginosa; Tazobactam

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CLAVULANIC ACID; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TICARCILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 0035564459     PISSN: 10687777     EISSN: None     Source Type: Journal    
DOI: 10.1300/J100v05n03_05     Document Type: Article

References (16)

1. Respiratory tract pathogens isolated form patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
2. Survey of bloodstream infections due to gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997
3. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
4. Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999
5. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains
6. Pseudomonas, porins, pumps and carbapenems
7. Antibiotic susceptibility and mechanisms of β-lactam resistance in 1310 strains of Pseudomonas aeruginosa: A French multicentre study (1996)
8. β-lactamase inhibitor combinations with extended-spectrum penicillins: Factors influencing antibacterial activity against Enterobacteriaceae and Pseudomonas aeruginosa
9. Interactions of tazobactam and clavulanate with inducibly and constitutively expressed class 1 β-lactamase
10. Extended-spectrum β-lactamases in Pseudomonas aeruginosa
11. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin
12. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: Ready for prime time
13. Mechanisms of bacterial resistance to antimicrobial agents
14. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections
15. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin/tazobactam